Prescient Therapeutics finished the June quarter stronger than ever
Health & Biotech
Health & Biotech
Link copied to
Pick any ASX clinical-stage oncology stocks and it would be thrilled to finish the June quarter in a stronger position than Prescient Therapeutics (ASX:PTX) did.
This company is trialling its PTX-100 and PTX-200 drugs to fight aggressive blood cancers and developing a next-generation CAR-T platform called OmniCAR.
OmniCAR stands out from other CAR-T therapies by enabling clinicians to control activity, even once infused into patients. Prescient hopes this will avoid the common risk of CAR-T therapies where healthy cells can be attacked in the same way as cancer cells due to a lack of clinician control.
Prescient Therapeutics achieved several feats during the quarter and closed it with a healthy cash balance of $16.1 million.
Most notably, the company progressed its Phase 1b clinical study in PTX-200 against acute myeloid leukemia from 35mg/m^2 to 45mg/m^2 after positive signs at the former levels.
It also strengthened its ties with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) which will see Prescient get direct access to Peter Mac’s facilities and team of CAR-T experts as it seeks to develop OmniCAR.
Prescient Therapeutics began the current quarter on a positive note. Earlier this week it received more positive results from a Phase 1b trial in another drug candidate – PTX-100 which showed the drug was highly tolerated.
Prescient also announced the results of an in silico (computer simulated) immunogenicity testing program of OmniCAR.
Prescient shareholders have more to look forward to in the coming months with the company promising further updates in the coming months.
“The company thanks all shareholders for their ongoing support and looks forward to updating them as it works to bring effective new personalised cancer treatments to clinicians and their patients who need them,” it said.
Prescient’s share price has been on a tear in recent weeks as its news flow has progressed. It has grown from 10 cents to 18 cents in the past two months.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.